IMMUTEP LIMITED — Director's Dealing 2015

Aug 4, 2015

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity PRIMA BIOMED LIMITED (ASX:PRR) ABN 90 009 237 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Marc Voigt
Date of last notice	7 January 2015

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest		Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		N/A
Date of change		5 August 2015
No. of securities held prior to change		1) Ordinary Fully Paid Shares Shares Options Direct 870,000 1,171,754 Indirect - - Total 870,000 1,171,754 2) American Depositary Receipts (ADR) Shares Options Direct 150 - Indirect - - Total 150 - 3) 4,068,627 STI Performance Rights and 12,254,902 LTI Performance Rights in accordance with shareholder approval obtained at 2014 AGM.

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class		Ordinary Fully Paid Shares	Ordinary Fully Paid Shares
Number acquired		1) Ordinary Fully Paid Shares
			Shares	Options
		Direct	6,666,666	-
		Indirect	-	-
		Total	6,666,666	-
Number disposed		6,666,666 Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		Nil The Performance Rights were issued for a range of remuneration and incentive purposes in accordance with shareholder approval obtained at the Extraordinary General Meeting on 31 July 2015. No amount is payable upon exercise of the Performance Rights for shares after vesting.
No. of securities held after change		1) Ordinary Fully Paid Shares Shares Options Direct 7,536,666 1,171,754 Indirect - - Total 7,536,666 1,171,754 2) American Depositary Receipts (ADR) Shares Options Direct 150 - Indirect - - Total 150 - 3) 4,068,627 STI Performance Rights and 12,254,902 LTI Performance Rights in accordance with shareholder approval obtained at 2014 AGM. 4) 13,333,334 Performance Rights in accordance with shareholder approval obtained at the Extraordinary General Meeting on 31 July 2015.

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

	Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	1) 20,000,000 Performance Rights were issued in accordance with shareholder’s approval obtained at the Extraordinary General Meeting on 31 July 2015. The first tranche of 6,666,666 vested immediately upon approval. After vesting of the first tranche, 13,333,334 Performance Rights remain to be vested subject to Mr Voigt meeting his service conditions over 2 subsequent annual tranches. 2) Acquiring 6,666,666 shares upon exercise of the first tranche of performance rights. One ordinary fully paid share was acquired for each Performance Right that vested.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

Part 3 –[+] Closed period

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided, on what date was this provided?

05.08.2015

• See chapter 19 for defined terms.

Appendix 3Y Page 4

01/01/2011